Targeting Iron Metabolism and Ferroptosis as Novel Therapeutic Approaches in Cardiovascular Diseases DOI Open Access
Yufei Chen, Xueting Li, Siyuan Wang

et al.

Nutrients, Journal Year: 2023, Volume and Issue: 15(3), P. 591 - 591

Published: Jan. 23, 2023

Iron functions as an essential micronutrient and participates in normal physiological biochemical processes the cardiovascular system. Ferroptosis is a novel type of iron-dependent cell death driven by iron accumulation lipid peroxidation, characterized depletion glutathione suppression peroxidase 4 (GPX4). Dysregulation metabolism ferroptosis have been implicated occurrence development diseases (CVDs), including hypertension, atherosclerosis, pulmonary myocardial ischemia/reperfusion injury, cardiomyopathy, heart failure. chelators deferoxamine dexrazoxane, lipophilic antioxidants ferrostatin-1 liproxstatin-1 revealed to abolish suppress peroxidation other CVDs. Notably, inhibition has demonstrated alleviate cardiac impairments, fibrosis pathological remodeling during hypertension potentiating GPX4 signaling. Administration improved injury inhibiting peroxidation. Several small molecules may be effective treatment ferroptosis-mediated In this article, we summarize regulatory roles underlying mechanisms dysregulation Targeting are potential therapeutic strategies prevention

Language: Английский

The Role of Oxidative Stress in Cardiovascular Aging and Cardiovascular Diseases DOI Creative Commons
Carmine Izzo, Paolo Vitillo, Paola Di Pietro

et al.

Life, Journal Year: 2021, Volume and Issue: 11(1), P. 60 - 60

Published: Jan. 15, 2021

Aging can be seen as process characterized by accumulation of oxidative stress induced damage. Oxidative derives from different endogenous and exogenous processes, all which ultimately lead to progressive loss in tissue organ structure functions. The theory aging expresses itself age-related diseases. is fact a primary risk factor for many diseases particular cardiovascular its derived morbidity mortality. Here we highlight the role We take into consideration molecular mechanisms, structural functional alterations, accompanied process.

Language: Английский

Citations

117

Artificial sweeteners and risk of cardiovascular diseases: results from the prospective NutriNet-Santé cohort DOI Creative Commons
Charlotte Debras, Eloi Chazelas, Laury Sellem

et al.

BMJ, Journal Year: 2022, Volume and Issue: unknown, P. e071204 - e071204

Published: Sept. 7, 2022

Abstract Objectives To study the associations between artificial sweeteners from all dietary sources (beverages, but also table top sweeteners, dairy products, etc), overall and by molecule (aspartame, acesulfame potassium, sucralose), risk of cardiovascular diseases (overall, coronary heart disease, cerebrovascular disease). Design Population based prospective cohort (2009-21). Setting France, primary prevention research. Participants 103 388 participants web NutriNet-Santé (mean age 42.2±14.4, 79.8% female, 904 206 person years). Dietary intakes consumption were assessed repeated 24 h records, including brand names industrial products. Main outcomes measures Associations (coded as a continuous variable, log10 transformed) disease risk, multivariable adjusted Cox hazard models. Results Total sweetener intake was associated with increased (1502 events, ratio 1.09, 95% confidence interval 1.01 to 1.18, P=0.03); absolute incidence rate in higher consumers (above sex specific median) non-consumers 346 314 per 100 000 years, respectively. Artificial more particularly (777 1.06 1.31, P=0.002; rates 195 150 years non-consumers, respectively). Aspartame events (1.17, 1.03 1.33, P=0.02; 186 151 respectively), potassium sucralose (730 events; potassium: 1.40, 1.84, 167 164; sucralose: 1.00 1.71, P=0.05; 271 161). Conclusions The findings this large scale suggest potential direct association (especially aspartame, sucralose) risk. are present thousands food beverage brands worldwide, however they remain controversial topic currently being re-evaluated European Food Safety Authority, World Health Organization, other health agencies. Trial registration ClinicalTrials.gov NCT03335644

Language: Английский

Citations

104

Temporal trends in associations between severe mental illness and risk of cardiovascular disease: A systematic review and meta-analysis DOI Creative Commons
Amanda Lambert, Helen Parretti, Emma Pearce

et al.

PLoS Medicine, Journal Year: 2022, Volume and Issue: 19(4), P. e1003960 - e1003960

Published: April 19, 2022

Background Severe mental illness (SMI; schizophrenia, bipolar disorders (BDs), and other nonorganic psychoses) is associated with increased risk of cardiovascular disease (CVD) CVD-related mortality. To date, no systematic review has investigated changes in population level mortality over calendar time. It unclear if this relationship changed time higher-income countries changing treatments. Methods findings address gap, a was conducted, to assess the association between SMI CVD including temporal change. Seven databases were searched (last: November 30, 2021) for cohort or case – control studies lasting ≥1 year, comparing frequency incidence high-income people versus without SMI. No language restrictions applied. Random effects meta-analyses conducted compute pooled hazard ratios (HRs) rate ratios, standardised (SMRs), odds (ORs), (RRs) those Temporal trends explored by decade. Subgroup analyses age, sex, setting, world region, study quality (Newcastle–Ottawa scale (NOS) score) conducted. The narrative synthesis included 108 studies, quantitative 59 (with (≥1,841,356 cases 29,321,409 controls) 28 (≥401,909 14,372,146 controls). higher than controls across most comparisons, except total BD cerebrovascular accident (CVA) mixed Estimated risks larger schizophrenia BD. Pooled results ranged from SMR = 1.55 (95% confidence interval (CI): 1.33 1.81, p < 0.001), CVA HR/rate ratio 2.40 CI: 2.25 2.55, 0.001) schizophrenia. For BD, SMRs HRs/rate CHD outcomes occurring during 1990s 2000s earlier decades (1980s: 1.14, 95% 0.57 2.30, 0.71; 2000s: 2.59, 1.93 3.47, 0.001 CHD) younger age. CVA, events, heart failure controls. 1.25 1.04 1.51, 0.016) events 3.82 3.1 4.71, failure. Incidence However, elevated higher-quality only. after 1990s. Study limitations include high bias some as they drew comparison general rates fact that it difficult exclude had overlapping populations, although attempts made minimise this. Conclusions In study, we found an approximate doubling mortality, particularly since 1990s, groups. also relative participants More research needed clarify ways mitigate risk.

Language: Английский

Citations

78

The Role of Interleukin-6 Family Members in Cardiovascular Diseases DOI Creative Commons

Yongqi Feng,

Di Ye, Zhen Wang

et al.

Frontiers in Cardiovascular Medicine, Journal Year: 2022, Volume and Issue: 9

Published: March 23, 2022

Cardiovascular disease is one of the main causes human mortality. Cytokines play crucial roles in development cardiovascular disease. Interleukin (IL)-6 family members are a series cytokines, including IL-6, IL-11, IL-30, IL-31, OSM, LIF, CNTF, CT-1, CT-2, and CLC, that regulate multiple biological effects. Experimental clinical evidence shows IL-6 closely related to diseases such as atherosclerosis, hypertension, aortic dissection, cardiac fibrosis, cardiomyopathy. This review mainly discusses role for sake identifying possible intervention targets prevention treatment.

Language: Английский

Citations

77

Targeting Iron Metabolism and Ferroptosis as Novel Therapeutic Approaches in Cardiovascular Diseases DOI Open Access
Yufei Chen, Xueting Li, Siyuan Wang

et al.

Nutrients, Journal Year: 2023, Volume and Issue: 15(3), P. 591 - 591

Published: Jan. 23, 2023

Iron functions as an essential micronutrient and participates in normal physiological biochemical processes the cardiovascular system. Ferroptosis is a novel type of iron-dependent cell death driven by iron accumulation lipid peroxidation, characterized depletion glutathione suppression peroxidase 4 (GPX4). Dysregulation metabolism ferroptosis have been implicated occurrence development diseases (CVDs), including hypertension, atherosclerosis, pulmonary myocardial ischemia/reperfusion injury, cardiomyopathy, heart failure. chelators deferoxamine dexrazoxane, lipophilic antioxidants ferrostatin-1 liproxstatin-1 revealed to abolish suppress peroxidation other CVDs. Notably, inhibition has demonstrated alleviate cardiac impairments, fibrosis pathological remodeling during hypertension potentiating GPX4 signaling. Administration improved injury inhibiting peroxidation. Several small molecules may be effective treatment ferroptosis-mediated In this article, we summarize regulatory roles underlying mechanisms dysregulation Targeting are potential therapeutic strategies prevention

Language: Английский

Citations

65